Invicta Diagnostic Limited Marks Entry into Nashik Through Strategic Acquisition

Acquisition Details

The Company will acquire up to 95% equity stake in Vinchurkar Diagnostics Private Limited in two tranches. The first tranche involves acquisition of 51% shareholding by 31st May, 2026, followed by a second tranche of up to 44% shareholding by 31st October, 2026. The acquisition will be undertaken through cash consideration, with a total consideration of ₹7.60 Cr.

About Vinchurkar Diagnostics Private Limited

Vinchurkar Diagnostics Private Limited, established in 1993, is a well-established diagnostic services provider based in Nashik, Maharashtra. The company offers a comprehensive range of diagnostic services including CT, MRI, mammography, and other diagnostic tests, and is known for its 24/7 service capability. It has been a pioneer in the region, being the first private diagnostic centre in Nashik to introduce CT and Mammography in 1995, followed by MRI in 1999 and Superconducting MRI in 2004.

For FY 25, Vinchurkar Diagnostics reported a turnover of ₹4.45 Cr, reflecting its established operations and strong regional presence in the Nashik market.

Strategic Impact of the Acquisition

Upon completion, the acquisition is expected to support Invicta Diagnostic Limited’s expansion into Nashik and strengthen its regional footprint beyond the Mumbai Metropolitan Region. The move aligns with the Company’s strategy to scale its diagnostic network across Maharashtra, enhance service reach, and deepen its presence in high-potential regional markets.

Commenting on the development, Mr. Sanket Vinod Jain, Chairman and Non-Executive Director of Invicta Diagnostic Limited, said, “This acquisition aligns with our strategy to expand beyond the Mumbai Metropolitan Region and strengthen our presence across key markets in Maharashtra. Nashik is a high-potential healthcare market, and our entry into the region supports our long-term growth plans.” We are acquiring an already established and reputed diagnostic player with a strong legacy and deep-rooted presence in the local market. This allows us to leverage existing capabilities, enhance service offerings, and drive operational synergies, while continuing to deliver high-quality diagnostic services to a wider patient base.”

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.